Dr. Bo Lu to Lead the Radiation Therapy Oncology Group's Lung Cancer Translational Research Program
Philadelphia, PA—The Radiation Therapy Oncology Group (RTOG) announced that Bo Lu, MD, PhD, of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has been appointed chair of the group's Translational Research Program (TRP) Committee's Lung Cancer Subcommittee. The RTOG TRP Committee supports the integration of new scientific discoveries into the design of multi-center clinical trials.
Bo Lu, MD, PhD, of Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson.
Dr. Lu is professor in the Department of Radiation Oncology at Jefferson, where he also serves as director of the department's Division of Molecular Radiation Biology. Prior to joining Jefferson in early 2011, Dr. Lu was associate professor in the Departments of Radiation Oncology and Cancer Biology at Vanderbilt University School of Medicine and director of the Department of Radiation Oncology's translational research program. He is also a visiting professor of radiation oncology at Tianjin Medical University Cancer Hospital, in Tianjing, China.
"As a member of RTOG's Translation Research Program Committee since 2009, it has been exciting to be part of research efforts incorporating novel cancer treatment strategies into the design of early phase, multicenter clinical trials," says Dr. Lu. Among Dr. Lu's basic science research interests are the development of drugs that cause tumor cells to be more sensitive to radiation therapy and that target lung cancer stem cells.
"Dr. Lu is internationally renowned for his work in translational radiation oncology, and I am enthusiastic about his leadership role with regard to guiding the RTOG's translational research agenda in lung cancer," says Adam Dicker, MD, PhD, Professor and Chairman of Radiation Oncology at Thomas Jefferson University and RTOG's Translational Research Program Chair. "He has demonstrated talent for applying findings from the laboratory into clinical research," remarks Dr. Dicker.
"Dr. Lu's extensive basic science background and insight about promising new agents will be a tremendous asset to RTOG's Lung Cancer Committee," says committee chair and radiation oncologist Jeffrey Bradley, MD, Associate Professor of Radiation Oncology at Washington School of Medicine. Dr. Bradley adds, "I anticipate an exciting and productive collaboration."
"The opportunity to work with RTOG colleagues to advance new treatment options and improve clinical care for lung cancer patients is very rewarding," says Dr. Lu, "and I am pleased to assume an expanded role within a research organization that promotes the robust evaluation of new therapeutic approaches in radiation oncology."
Dr. Lu received his PhD in cell and molecular biology from Baylor School of Medicine and his doctorate in medicine from Shanghai Medical University in China. He completed his residency in radiation oncology at the University of Southern California. Dr. succeeds Quynh Le, MD, PhD from Stanford University who recently was named chair of RTOG's Head and Neck Cancer Committee.
"An important goal at the Kimmel Cancer Center is to foster translational medicine — taking basic science research and moving it closer to clinical practice," said Richard Pestell, MD, PhD, FACP, Director of the Kimmel Cancer Center at Jefferson. "With his lab investigations focusing on just that, and now this appointment to RTOG's lung cancer subcommittee, Dr. Lu will no doubt help us discover safer and more effective treatments for patients suffering from this disease."
For more information about RTOG and the group's Translational Research Program: www.rtog.org.
For more information, contact: Jennifer McGowan Smith, Thomas Jefferson University and Hospital, 211 South 9th Street, Suite 310, Philadelphia, PA 19107, (215) 955-5507, (215) 955-5008 fax, or email email@example.com.